Table 3.

Tetrachloroethylene exposure history of breast cancer subjects, adjusted^a odds ratios, and 95% confidence intervals.

	Latency period, years	Exposed Cases	Exposed Controls	Adjusted ORs (95 % CI)
0	Non-proxy Subjects	101	88	1.1 (0.8–1.5)
	All Subjects	155	136	1.1 (0.8–1.4)
5	Non-proxy Subjects	87	69	1.2 (0.9–1.8)
	All Subjects	129	107	1.2 (0.9–1.6)
7	Non-proxy Subjects	71	61	1.1 (0.8–1.6)
	All Subjects	111	96	1.1 (0.8–1.5)
9	Non-proxy Subjects	63	57	1.1 (0.7–1.6)
	All Subjects	97	85	1.1 (0.8–1.5)
11	Non-proxy Subjects	49	43	1.1 (0.6–1.7)
	All Subjects	79	65	1.2 (0.8–1.7)
13	Non-proxy Subjects	43	32	1.3 (0.7–2.1)
	All Subjects	61	45	1.3 (0.9–2.0)
15	Non-proxy Subjects	30	21	1.4 (0.7–2.6)
	All Subjects	44	31	1.4 (0.9–2.3)
17	Non-proxy Subjects	15	15	1.0 (0.4–2.2)
	All Subjects	21	21	1.0 (0.6–2.0)
19	Non-proxy Subjects	6	6	1.1 (0.3–3.5)
	All Subjects	9	9	1.1 (0.4–2.9)

^a The OR was calculated relative to never-exposed cases (n = 360 for Non-Proxy, n = 517 for ALL) and controls (n = 336 for Non-Proxy, n = 480 for All). Controlled for age at diagnosis or index year, family history of breast cancer, personal history of breast cancer (before current diagnosis or index year), age at first live-birth or still birth, occupational exposure to PCE, and vital status at interview (for All analysis only).